Connect your AI

Bristol-Myers Squibb BMY Long-Term Debt

Long-Term Debt at other companies

PfizerPFE

$60.57B+5.1%

Johnson & JohnsonJNJ

$37.34B-4.8%

Merck & Co.MRK

$49.1B+41.1%

Gilead SciencesGILD

$20.86B-5.8%

CytokineticsCYTK

$247.21M+169%

ImmunityBio, Inc.IBRX

$404.3M+36.5%

Other financials

Income statement

Revenue$13.0B+5.7%

Gross profit$9.2B+3.9%

Net income$3.3B+153%

EPS (diluted)$1.62+153%

Balance sheet

Cash & equivalents$8.7B-30.8%

Total debt$43.3B-12.3%

Total equity$22.3B+28.0%

Total assets$87.6B-7.4%

Cash flow

Operating cash flow$3.4B-13.4%

CapEx$305.0M-15.5%

Free cash flow$3.1B-13.2%

Valuation

Market cap$129.88B+36.2%

Enterprise value$164.48B+24.5%

P/E14×-5.2×

P/S2.6×+0.6×

Profitability

Gross margin70.2%-0.1pp

Net margin18.9%+8.4pp

FCF margin23.3%-7.3pp

Returns & leverage

Return on equity46.7%+17.8pp

Debt / equity1.9×-0.9×

Current ratio1.5×+0.3×

Where this comes from

Reported directly by Bristol-Myers Squibb in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebtNoncurrent.

The official record: Bristol-Myers Squibb’s 10-Q, filed July 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bristol-Myers Squibb's long-term debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Bristol-Myers Squibb's long-term debt?: Bristol-Myers Squibb (BMY) reported long-term debt of $42.09B in Q2 2026.
How has Bristol-Myers Squibb's long-term debt changed year-over-year?: Bristol-Myers Squibb's long-term debt decreased by 5.3% year-over-year, from $44.47B to $42.09B.
What is the long-term trend for Bristol-Myers Squibb's long-term debt?: Over 5 years (2020 to 2025), Bristol-Myers Squibb's long-term debt has grown at a -2.4% compound annual growth rate (CAGR), from $48.34B to $42.85B.
What does long-term debt mean?: Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.